Merck unexpectedly discontinued Recarbrio from the U.S. market earlier this month, emphasizing ongoing concerns regarding large pharmaceutical companies’ commitment to the critical public health field of antibiotic development. The drug, which was approved seven years ago, served as a crucial treatment option for serious infections—such as hospital-acquired pneumonia and complicated urinary tract infections—in adults and children with limited alternative choices.

According to data cited from The Lancet, bacterial antimicrobial resistance (AMR) is projected to cause 39 million direct deaths between 2025 and 2050, accompanied by severe economic consequences including a projected annual hit of up to $3.4 trillion to global GDP by 2030. While clinical innovations like the newly approved oral carbapenem Utebzi (tebipenem pivoxil) offer hospital-sparing alternatives for resistant infections, the pipeline faces commercial obstacles because novel antibiotics must be used selectively to preserve their efficacy. Ultimately, modeling indicates that widely optimizing healthcare delivery and infection prevention could save up to 92 million lives by 2050, which is roughly eight times the number of deaths that new antibiotics alone could prevent.

A before-and-after study evaluated an optimized blood culture workflow in 260 ICU patients with bloodstream infections, including rapid antimicrobial susceptibility testing (AST) reporting and dual AST cards. Following implementation, AST results were available 19.6 hours earlier (p<0.001), with significantly reduced use of meropenem and tigecycline. Hospital length of stay decreased by 5 days (p=0.006), while antibiotic costs were 4,871 CNY (approximately US$684) lower per patient. These findings suggest that rapid diagnostic workflows may facilitate earlier targeted therapy, support antimicrobial stewardship and reduce healthcare resource use, although the observational design limits causal interpretation.

A hospital-based study evaluated a combined intervention integrating antibiotic education for patients and healthcare professionals with an intelligent prescription pre-audit system. The intervention was associated with reduced antibiotic use density and antibiotic expenditure, alongside fewer inappropriate prescriptions related to treatment indications, dosing, administration routes and contraindications. These findings suggest that integrating health literacy initiatives with digital prescription decision-support tools may improve rational antibiotic use and strengthen antimicrobial stewardship in county-level hospitals, although further evaluation is needed to establish effectiveness.